LeMaitre Vascular Q2 2023 Earnings Report $91.62 +0.69 (+0.76%) (As of 01:34 PM ET) Earnings HistoryForecast LeMaitre Vascular EPS ResultsActual EPS$0.37Consensus EPS $0.32Beat/MissBeat by +$0.05One Year Ago EPSN/ALeMaitre Vascular Revenue ResultsActual Revenue$50.12 millionExpected Revenue$48.29 millionBeat/MissBeat by +$1.83 millionYoY Revenue GrowthN/ALeMaitre Vascular Announcement DetailsQuarterQ2 2023Date8/1/2023TimeN/AConference Call ResourcesPress ReleaseLMAT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by The #1 Coin for November 2024 (Ad)‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED! Click here to get all the details on this crypto coin now. LeMaitre Vascular Earnings HeadlinesLeMaitre Vascular Announces $150 Million Convertible Senior Notes OfferingUnited States-based medical device company LeMaitre Vascular, Inc. (NASDAQ: LMAT) revealed its plans for a substantial financial move on December 16, 2024. The company discloseDecember 18 at 2:05 AM | americanbankingnews.comLeMaitre Vascular Prices $150M Convertible Notes OfferingDecember 17 at 8:50 PM | markets.businessinsider.comThe #1 Coin for November 2024‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED! December 18, 2024 | Crypto 101 Media (Ad)LeMaitre Vascular Prices $150 Million Convertible Senior NotesDecember 17 at 5:46 AM | markets.businessinsider.comLeMaitre Vascular prices $150M convertible senior notesDecember 17 at 5:46 AM | msn.comLeMaitre Vascular To Offer $150 Mln Of Senior Notes; Pre-Market Stock DownDecember 16 at 10:22 AM | markets.businessinsider.comSee More LeMaitre Vascular Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LeMaitre Vascular? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LeMaitre Vascular and other key companies, straight to your email. Email Address About LeMaitre VascularLeMaitre Vascular (NASDAQ:LMAT) develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.View LeMaitre Vascular ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.